Posted by Michael Wonder on 01 Feb 2018
Sanofi, DNDi seek European Medicines Agency review for sleeping sickness treatment
1 February 2018 - Dossier will be reviewed under the Article 58 procedure, which is intended for medicines that will be used outside of the European Union.
Sanofi has asked the EMA to review fexinidazole for the treatment of sleeping sickness. Fexinidazole is being developed in collaboration with the Drugs for Neglected Disease initiative (DNDi).
It would be the first all-oral treatment under investigation for Trypanosoma brucei gambiense human African trypanosomiasis (g-HAT), commonly known as sleeping sickness. It is hoped that this treatment will contribute to the elimination of the disease.
